云南白药(000538) - 2015 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2015 reached ¥20,738,126,205.08, representing a year-on-year increase of 10.22% compared to ¥18,814,366,372.74 in the previous year[3] - Net profit attributable to shareholders was ¥2,770,841,401.07, reflecting a growth of 10.56% from ¥2,506,076,501.86 in the prior year[3] - The basic earnings per share increased to ¥2.66, up 10.56% from ¥2.41 in the previous year[3] Assets and Equity - The company's total assets at the end of the reporting period were ¥19,290,940,366.09, an increase of 18.05% from ¥16,341,340,193.50 at the beginning of the period[4] - Shareholders' equity attributable to the company reached ¥13,433,010,080.46, marking a 20.10% increase from ¥11,185,065,653.68[4] Strategic Initiatives - The company implemented an innovation-driven strategy, achieving a net profit growth of 15.37% after excluding non-recurring gains and losses[5] - The board of directors emphasized the importance of proactive management and strategic adjustments to ensure sustained growth[4] Challenges and Outlook - The company faced challenges due to stricter medical insurance cost control and price reductions in the pharmaceutical industry, leading to a difficult transition period[5] - The weighted average return on net assets decreased to 22.43%, down from 24.86% in the previous year, indicating a decline of 2.43 percentage points[3] - The company did not issue any performance forecasts or revisions for the reporting period[6]